Nationally Recognized Heart Hospital
Dallas   Fort Worth

Find a Physician

Advanced Search

Registrational Study With Omecamtiv Mecarbil/AMG 423 to Treat Chronic Heart Failure With Reduced Ejection Fraction (GALACTIC-HF)

Research area:
Heart Failure
Principal investigator:
Susan Joseph, MD
Type of study:

Study synopsis:
The purpose of this study is to determine if treatment with omecamtiv mecarbil/AMG 423 when added to standard of care is well tolerated and superior to a placebo in reducing the risk of cardiovascular death or heart failure events in subjects with chronic HFrEF..

Study objective:
The study will evaluate several outcomes measures including:

  • Evaluate the effect of omecamtiv mecarbil/AMG 423 as compared with a placebo in subjects with chronic heart failure with reduced ejection fraction receiving standard of care therapy
  • Measure changes in patient reported outcomes Kansas City Cardiomyopathy Questionnaire total symptom score to evaluate effect of treatment with omecamtiv mecarbil/AMG 423 on changes in patient reported outcomes
  • Evaluate effects of omecamtiv mecarbil/AMG 423 to first heart failure hospitalization
  • Evaluate effects of omecamtiv mecarbil/AMG 423 to all-cause death
  • Evaluate safety of oecamtiv mecarbil/AMG 423 by measuring incidence of reported adverse events, incidence of reported serious adverse events of ventricular arrhythmias requiring treatment
  • Measure incidence of positively adjudicated major cardiac ischemic events

Main/critical inclusion and exclusion criteria:
A complete list of inclusion and exclusion criteria can be found at:
Study contact:
Taylor Poyner, BSN, RN,

Back to Clinical Trials


Your Session will expire in 5 minutes

Please click the "Continue Session" button below to continue using the website. To end your session please click the "End Session" button below. After 5 minutes of inactivity your session will be terminated and you will be required to log in again.